Clinical trial · no report yet · Phase 3
API-CAT
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
- NCT03692065 ↗
- Completed
- Assistance Publique - Hôpitaux de Paris
- 18 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 9 | |
| X threads | 7 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Long-term Treatment of Cancer Associated VTE: Reduced vs Full Dose of Apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Cancer-associated Thrombosis
- Interventions
- Apixaban 5 MG
- Arms
- Apixaban film coated tablets 2.5 mg · Active comparator
- Apixaban film coated tablets 5 mg · Active comparator
- Enrollment
- 1,766
- Primary outcomes
- The incidence of an an adjudicated composite endpoint
- Sponsor
- Assistance Publique - Hôpitaux de Paris with Bristol-Myers Squibb
- Start
- Oct 11, 2018
- Primary completion
- Sep 6, 2024
- Results posted
- No
- Registry record
- NCT03692065 · updated Feb 6, 2025
Publications
linked from the registry- Mahe I, Happe F, Monreal M, Robert-Ebadi H, Debourdeau P, Fabreguettes JR, Accassat S, Mismetti P, Girard P, Laporte S, Chapelle C. API-CAT investigators' decisions on anticoagulation following extended treatment for cancer-associated thrombosis. Eur Heart J Cardiovasc Pharmacother. 2026 Sep 22;12(6):447-457. doi: 10.1093/ehjcvp/pvag046. PubMed 42361291
- Mahe I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P; API-CAT Study Group; API-CAT Investigators. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial. Lancet Haematol. 2026 Jan;13(1):e41-e48. doi: 10.1016/S2352-3026(25)00291-1. Epub 2025 Dec 6. PubMed 41365312
- Mahe I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, Lopez-Nunez JJ, Otero-Candelera R, Le Gal G, Yeo E, Righini M, Robert-Ebadi H, Huisman MV, Klok FA, Westerweel P, Agnelli G, Becattini C, Bamias A, Syrigos K, Szmit S, Torbicki A, Verhamme P, Maraveyas A, Cohen AT, Ay C, Chapelle C, Meyer G, Couturaud F, Mismetti P, Girard P, Bertoletti L, Laporte S; API-CAT Investigators. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2025 Apr 10;392(14):1363-1373. doi: 10.1056/NEJMoa2416112. Epub 2025 Mar 29. PubMed 40162636